Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lixumistat

Next Previous
Drug Profile

Lixumistat

Alternative Names: IM-156

Latest Information Update: 31 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoMet Therapeutics
  • Class Antifibrotics; Antineoplastics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Angiogenesis inhibitors; Mitochondrial oxidative phosphorylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis; Malignant melanoma; Pancreatic cancer
  • Preclinical Gastrointestinal stromal tumours; Glioblastoma; Prostate cancer
  • No development reported Solid tumours

Most Recent Events

  • 31 Jan 2025 Lixumistat is still in phase I development in Idiopathic-pulmonary-fibrosis (In volunteers) in USA (PO) (ImmunoMet Therapeutics pipeline, January 2025)
  • 24 Jan 2025 Efficacy data from a phase Ib trial in Pancreatic cancer released by ImmunoMet Therapeutics
  • 24 Jan 2025 ImmunoMet Therapeutics plans a phase II trial for Idiopathic pulmonary fibrosis (PO) (ImmunoMet Therapeutics pipeline, January 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top